Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.

Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.

  • 0 views
  • 24 Oct, 2021
  • 1 location
Carbon Ion Radiotherapy for Atypical Meningiomas (MARCIE)

patients with atypical meningiomas after incomplete resection or biopsy. Primary endpoint is progression-free survival rate, secondary endpoints are overall survival, safety and toxicity.

atypical meningioma
malignant meningioma
  • 42 views
  • 03 Mar, 2022
  • 1 location
Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults

Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib

Accepts healthy volunteers
  • 0 views
  • 24 Mar, 2022
  • 1 location
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. …

recurrent meningioma
blood transfusion
recurrent disease
neutrophil count
hysterectomy
  • 1 views
  • 08 Jun, 2022
  • 6 locations
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Background More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective …

sarcoma
neutrophil count
cancer
pineoblastoma
gliosarcoma
  • 120 views
  • 16 Jun, 2022
  • 11 locations
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD), food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS neoplasms.

nitrosourea
cancer chemotherapy
cytotoxic chemotherapy
oligodendroglioma
cancer
  • 10 views
  • 12 Mar, 2022
  • 1 location
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas (TransMenAtyp)

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical

  • 0 views
  • 13 Mar, 2022
  • 1 location
Oncological Care for Patients With Meningioma (ATYPICMENING)

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological diagnosis of GIIM criteria were changed in 2007 and might be viewed by some as being quite subjective. "Standards of care" and consensus do not …

  • 5 views
  • 03 May, 2022
  • 1 location
Rare CNS Tumors Outcomes &Risk

Background Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for <2% of all cancers diagnosed in the United States. Some of these tumors occur in less than 2,000 people per year. Researchers want to study a large …

medulloblastoma
sarcoma
pnet
meningioma
atypical teratoid/rhabdoid tumor
  • 41 views
  • 19 Jun, 2022
  • 1 location
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with …

  • 0 views
  • 19 Mar, 2021
  • 1 location